Compugen Ltd. (TLV:CGEN)

Market Cap	528.69M
Revenue (ttm)	101.49M
Net Income (ttm)	-51.83M
Shares Out	n/a
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,929
Average Volume	74,948
Open	569.80
Previous Close	558.20
Day's Range	556.80 - 570.20
52-Week Range	512.00 - 958.90
Beta	2.99
RSI	37.82
Earnings Date	Mar 4, 2025

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 74
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: CGEN

Financial Performance

In 2024, Compugen's revenue was $27.86 million, a decrease of -16.72% compared to the previous year's $33.46 million. Losses were -$14.23 million, -24.12% less than in 2023.

Financial numbers in USD